Physician profile
Lafitte Jermaine Holmes
NPI 1013217876
$13,256.27
in general payments reported to CMS, 2019-2025
49 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 94% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,725 · 2022: $2,672 · 2023: $2,398 · 2024: $2,726 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,845 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,845.06 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,834.79 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,790.71 | 2021-2025 | |
| Lilly USA, LLC | $1,114.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,022.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $868.88 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $734.23 | 2021-2025 | |
| Esperion Therapeutics, INC. | $481.57 | 2021-2024 | Nexletol, Nexlizet |
| Amgen INC. | $389.57 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.18 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $354.98 | 2021-2025 | Capvaxive, Belsomra, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $322.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.58 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $286.78 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $284.10 | 2021-2023 | Veozah, Myrbetriq |
| Abbott Laboratories | $267.03 | 2021-2025 | Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lafitte Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.